US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

Imunon, Inc. (NASDAQ:IMNN), a pharmaceutical preparations company currently trading at $1.32 with a market capitalization of $29.2 million, has regained compliance with Nasdaq’s minimum bid ...

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of ...

Imunon, Inc. (NASDAQ:IMNN), a pharmaceutical preparations company currently trading at $1.32 with a market capitalization of $29.2 million, has regained compliance with Nasdaq’s minimum bid price ...

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral ...

LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy ...

In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate ...

Imunon, Inc. (NASDAQ:IMNN), a company operating in the biotechnology sector, is part of key market indexes such as the Top ...

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001's Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral ...

LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today closed on the previously ...